Bromhexine

Quick links to important sections

Bromhexine

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromhexine

Property Description
Active ingredient Bromhexine Hydrochloride
Form Tablet, Oral Solution (Syrup/Elixir), Injection
Pharmacological class Mucolytic Agent / Secretolytic Agent
General purpose Clearing thick respiratory mucus
Origin Synthetic derivative (of vasicine)

Bromhexine is a pharmaceutical substance globally classified as a mucolytic agent and secretolytic agent, which is clinically recognized for its ability to modify and aid in the clearance of thick secretions from the respiratory tract. The core compound acting as the medicine's active ingredient is Bromhexine Hydrochloride. This substance is a synthetic derivative stemming from the natural alkaloid vasicine, ensuring a consistent and stable single-active-ingredient product. Bromhexine is assigned to the group of Mucolytics, which emphasizes its primary function in aiding the liquefaction of respiratory tract secretions.

Definition and Core Function

The primary role of Bromhexine is to reduce the thickness and stickiness (viscosity) of accumulated bronchial secretions, thereby making the phlegm easier to move and expectorate. As a secretolytic agent, its function involves actively breaking down the structure of the phlegm, specifically the complex mucopolysaccharide fibers present in tenacious secretions. This action is the core general purpose of the medication, designed to address the congestion associated with a productive cough in bronchopulmonary diseases. This property is associated with improved expectoration in cases involving high-viscosity mucus.

Forms, Types, and Composition

Bromhexine is commonly available as a single-ingredient product in several dosage forms suited for oral administration, including standard tablets and oral solutions (syrups or elixirs), with some formulations also available for parenteral use. The chemical entity is Bromhexine Hydrochloride (C14H20Br2N2 cdot HCl), which is the component responsible for the therapeutic effect. Depending on the final product, the active ingredient is combined with either a solid excipient base for tablets or an aqueous solution base for liquid preparations.

What side effects are possible with Bromhexine?

Possible Side Effects and Safety Information

The safety profile for Bromhexine Hydrochloride is organized by regulatory agencies based on the systems affected and the frequency of occurrence. The majority of documented adverse reactions are generally uncommon and relate to the gastrointestinal tract.

Official Adverse Reaction Scope

Classification Examples of Reactions Affected System-Organ Class
Uncommon Nausea, Vomiting, Diarrhoea, Upper Abdominal Pain Gastrointestinal Disorders
Rare General Hypersensitivity Reactions, Rash, Urticaria Immune System & Skin
Not Known Anaphylactic Shock, Angioedema, Severe Cutaneous Adverse Reactions (SCARs) including SJS/TEN Immune System & Skin

Serious Adverse Reactions and Safety Constraints

Official labeling specifically documents the potential for rare but serious adverse reactions, notably Anaphylactic Shock and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These reactions, which fall under the 'Not Known' frequency category, require explicit mention in safety documentation.

Regulatory safety statements also mandate caution regarding severe hepatic impairment and severe renal failure, as reduced clearance in these conditions may lead to an increased risk of drug accumulation. Additionally, caution is noted for individuals with a history of pre-existing peptic ulceration, and the use of Bromhexine is generally not recommended during the first trimester of pregnancy.

These classifications and constraints reflect how government regulatory bodies formally structure the medicine’s risk profile, distinguishing between commonly experienced effects and rare, clinically significant events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that no specific overdose symptoms have been reported for Bromhexine. In cases of accidental overconsumption or medication error, the documented manifestations are generally consistent with the known side effects of the medicine.

Documented Manifestations and Serious Outcomes

Overdose exposure may present as an exaggeration of typical adverse effects, affecting multiple body systems. Reported manifestations include gastrointestinal effects (nausea, vomiting, diarrhoea, upper abdominal pain) and systemic signs (headache, dizziness, sweating). Observed allergic or dermatological findings include skin rashes, urticaria, and angioedema.

The official risk profile is centered on severe hypersensitivity reactions. Documented serious outcomes requiring emergency intervention include anaphylactic reaction, potential for anaphylactic shock, and acute respiratory signs like bronchospasm or difficulty in breathing.

Required Emergency Action

Regulatory authorities mandate specific actions for suspected overconsumption. You must immediately telephone your doctor, pharmacist, or the Poisons Information Centre or local emergency service. Urgent medical attention must be sought immediately, even if the patient does not notice any signs or symptoms.

Management for overconsumption focuses on supportive care. No specific antidote is officially documented or known, and treatment consists solely of providing symptomatic and supportive treatment to manage clinical manifestations.

Therapeutic Uses of Bromhexine

What Bromhexine Treats: Main Uses and Benefits

Bromhexine is generally used to help manage symptoms related to a chesty, productive cough where the associated mucus is stubbornly thick and difficult to expel (expectorate). It is relevant in clinical settings that involve acute or unstable symptom patterns, such as those seen in acute bronchitis and seasonal respiratory infections. A primary indication for the substance is to 'Help clear chest congestion.' The key therapeutic benefit provided is the easing of the physical burden by assisting with the management of thick secretions, which supports the patient during difficult episodes by addressing the symptomatic discomfort.


The medication is applied across domains where additional symptomatic support is needed to address chest congestion and respiratory discomfort related to thick, viscous mucus. It is considered relevant for use in chronic conditions such as exacerbations of chronic bronchitis or COPD, as well as in acute settings like pneumonia, where functional stability becomes affected by accumulated phlegm. Common indications include acute tracheobronchitis, chronic obstructive pulmonary disease (COPD), and general respiratory tract infections where symptoms are related to thick, excessive secretions. The benefit contributes to improved comfort during periods of heightened symptoms by helping to clear the airways, thereby supporting symptomatic relief.


The medication plays a role in managing symptoms that create noticeable functional strain. It is commonly used as an adjunct treatment alongside antibiotics in severe respiratory tract infections. This use is relevant for easing challenging symptoms by supporting the mobilization and clearance of stubborn secretions, offering symptomatic relief that generally helps patients cope more steadily with difficult episodes.

Quick Fact: Supports Management of Thick, Stubborn Phlegm

Regulatory References

  1. Therapeutic Goods Administration (TGA) OTC Medicine Monograph

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bromhexine — official regulatory information

Eligibility scope

  • Populations for whom use is allowed (as stated in label): Adults and children 6 years of age and over are generally eligible for standard labeled use.
  • Populations for whom use is not recommended (if applicable): Pregnant women (especially in the first trimester), breastfeeding mothers, and children under six years of age in many regulatory markets.
  • Populations for whom use is contraindicated: Patients with known hypersensitivity to the active substance or its excipients. Specific liquid formulations are also contraindicated in patients with rare hereditary problems of fructose intolerance.
  • Age-related eligibility rules: Approved for use in 12 years and over; use is restricted or not recommended for children under 6 years of age.
  • Condition-specific eligibility rules: Use is restricted and requires caution in patients with severe hepatic impairment, severe renal impairment (due to reduced drug clearance), or a history of peptic ulceration.
  • Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy: Not recommended, especially in the first trimester. Lactation: Should not be used as the substance is excreted in breast milk.
  • Eligibility-related restrictions: Use with caution is advised for patients with existing or a history of gastric ulceration.

Eligibility classifications (high-level)

  • Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, Use with Caution.
  • Regulatory basis: Eligibility is based on SmPC documents and national health authority guidelines.
  • Eligibility-context constraints (as defined in official documents): Hypersensitivity, Organ Dysfunction, Age, and Reproductive Status.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents strictly define the eligibility profile of Bromhexine by classifying specific populations as contraindicated or subject to conditional restrictions. The profile sets clear age-based limitations and advises that the medicine is not recommended for use during pregnancy or lactation due to data limitations or excretion into breast milk, thus regulating who can and cannot use the medicine under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Bromhexine Hydrochloride based on specific pharmacodynamic and pharmacokinetic effects, which mandate certain administration restrictions.

Pharmacodynamic and Administration Restrictions

Co-administration with antitussives (cough suppressants) or secretion-drying medications is officially restricted. This prohibition is based on a pharmacodynamic antagonism, as suppressing the cough reflex or reducing secretions risks the accumulation of the thinned bronchial mucus.

Documented Exposure Changes

Bromhexine is documented to alter the local exposure of certain antibiotics. Co-administration has been shown to increase the concentration of antibiotics, including amoxycillin, erythromycin, and oxytetracycline, specifically in the sputum and bronchopulmonary secretions. Systemic exposure is also affected by food; concomitant food intake officially results in an increase in Bromhexine plasma concentrations.

Official Constraints

Constraint Type Details
Timing-Separation None documented requiring mandatory time separation of doses.
Population Note Clearance of Bromhexine or its metabolites may be reduced in patients with severe hepatic or renal impairment.
Excipient Constraint Formal caution is required for products containing excipients like Maltitol, Sorbitol, or Lactose in patients with corresponding hereditary intolerances, as noted in the product information.

Mechanism of Action

How Bromhexine Works

Bromhexine functions primarily as a mucolytic agent through two integrated mechanistic domains. The direct mechanism involves acting on the complex molecular architecture of bronchial secretions. Specifically, it targets and initiates the depolymerization of the acid mucopolysaccharide fibers by hydrolyzing their intricate bonds. This interaction results in a fundamental reduction in the viscosity and elasticity of the high-molecular-weight secretions, modifying their rheological properties.

The second domain addresses the secretory function of the respiratory tract lining. The mechanism involves the modulation of mucociliary function via the stimulation of the serous-secreting glands. This cellular action increases the volume of the periciliary fluid (serous mucus), which is thinner and more watery. Coupled with a potential influence on ciliary beat frequency, this increases the overall efficiency of the mucociliary transport system, resulting in the movement of secretions toward the upper airways.

Dosage and Administration Information

Official Administration Guidelines

Bromhexine is administered through multiple established routes, including Oral (tablets, syrups, and solutions), Intravenous (IV), and Intramuscular (IM) injection, with the latter two typically reserved for clinical settings or severe conditions. Dosage instructions vary by route, form, and age group, and follow standardized clinical documentation.

Dosing and Frequency

Age Group Standard Regimen (Oral) Maximum/Intensive Dose (Oral)
Adults & Children >12 8 mg three times daily (TID) Up to 16 mg three times daily for the first 7 days
Children 6–12 years 4 mg to 8 mg, three times daily Maximum 24 mg daily

The IV dosage is typically 8 mg to 16 mg daily, usually divided and administered in two or three slow injections. Treatment is generally intended for a short course and should not exceed 7 to 14 days without further medical re-evaluation.

Procedural Instructions

Oral forms can be taken with or without food; however, concomitant food intake is noted to increase plasma concentrations. For liquid formulations, the bottle should be shaken well before use. For intravenous administration, the injection must be diluted with specified solutions, such as 5% glucose or 0.9% sodium chloride, and should never be mixed with alkaline agents due to the risk of chemical precipitation. Dose adjustment is a specified procedural necessity for patients with severe hepatic or renal impairment due to reduced drug clearance. If a dose is missed, it is standard practice to skip the missed dose if it is close to the next scheduled dose, and double doses are avoided.

Recent Clinical Evidence

Evidence for Acute Respiratory Symptoms and Productive Cough

Bromhexine was studied in research exploring symptoms of chest congestion and productive cough, which are conditions involving periods of heightened symptoms, such as those seen in acute bronchitis. The research available includes Randomized Controlled Trials (RCTs) and scientific meta-analyses that research examined how symptoms change over time for patients dealing with thick respiratory secretions.

Studies primarily monitored measurements of patient-reported outcomes describing perceived discomfort and time frames for changes in cough and difficulties with expectoration (bringing up phlegm). Researchers also monitored and reported on measurable changes measured during the study period in sputum characteristics, such as its stickiness and volume.

Evidence in Chronic Conditions: COPD and Chronic Bronchitis

Bromhexine was also studied for its use as a supportive measure during flare-ups in conditions characterized by fluctuating or episodic manifestations, such as Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. The research examined these trials in the context of patient-reported outcomes describing perceived discomfort and changes in expectoration difficulty. The evidence is limited for major functional measures like standardized lung capacity tests, with some studies reporting how symptoms evolved in the observed populations but not observing significant changes in objective lung function.

Key Limitations and Uncertainty in the Evidence Base

Most clinical research on Bromhexine was evaluated in short-term settings, meaning the follow-up durations were limited. The overall evidence base presents several research limitation frames. Much of the evidence relies on older trials, meaning the evidence quality varies across studies due to differences in design and reporting standards compared to modern research. Furthermore, comparative evidence is lacking for many new standard treatments, making it challenging to contextualize the findings. For complex or chronic conditions, the data often focus only on patient-reported outcomes describing perceived discomfort and do not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. Bromhexine Product Information (TGA Regulatory Document)
  2. Bromhexine - Drugs and Lactation Database (LactMed®) - NIH
  3. Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Bromhexine (FAQ)

Q: What is the main difference between Bromhexine and other cough medicines?

Bromhexine is primarily classified as a mucolytic agent, meaning its main function is to chemically thin and break down the thick mucus in the airways. This action makes it functionally different from a cough suppressant (antitussive), which works by reducing or blocking the natural cough reflex.


Q: Is Bromhexine the same kind of drug as ambroxol?

According to chemical and regulatory information, ambroxol is considered a known metabolite, or breakdown product, of bromhexine. Due to this close chemical relationship, regulatory bodies often treat both drugs similarly regarding certain safety precautions, such as warnings about rare severe skin reactions.


Q: Is Bromhexine available without a prescription in some countries?

Yes, official drug listings show that Bromhexine is a medication that is widely available as an over-the-counter (OTC) medicine in many countries. It is commonly used for the temporary relief of cough symptoms associated with excessive mucus.


Q: Can Bromhexine be used for a dry cough?

Regulatory indications define Bromhexine as a treatment for respiratory conditions where the patient is experiencing a productive cough, which is a cough that produces thick sputum or phlegm. It is not officially indicated for the management of a non-productive (dry) cough.


Q: How quickly can a person expect to feel the effect of Bromhexine?

Pharmacokinetic data indicates that Bromhexine is absorbed rapidly after it is taken orally. However, its therapeutic action, involving chemically altering mucus, may take two to three days to fully manifest a therapeutic benefit in expectoration.


Q: What is the expected duration of the effects of Bromhexine after a single use?

Based on official product information, the active substance is retained in the body for a considerable time. The terminal elimination half-life, which is a pharmacokinetic measure of the time required to reduce the drug concentration by half, is reported to be up to approximately 12 hours.


Q: Are there any known issues with taking Bromhexine and alcohol?

Official product labeling notes that there are no significant known interactions between Bromhexine and alcohol. Regulatory information notes that it is general public health guidance to limit alcohol consumption when using any medicinal product.


Q: Can people with high blood pressure use Bromhexine?

High blood pressure (hypertension) is not listed as a contraindication or specific precaution in the official regulatory documents for Bromhexine. However, regulatory documents describe that caution is generally advised for any pre-existing severe cardiovascular conditions when taking over-the-counter medications.


Q: Is it true that Bromhexine is used in some veterinary medicines?

Yes, regulatory summary reports confirm that Bromhexine is also licensed for use in veterinary medicine. It is used to treat respiratory diseases in animals, including species such as calves, pigs, and poultry, to help clear thick mucus.


Q: Have there been studies looking at Bromhexine's role beyond clearing mucus?

Research has explored potential actions of Bromhexine that extend beyond its primary mucolytic properties, such as its ability to interfere with certain cellular or viral mechanisms. These secondary areas of study are not part of the drug's official, licensed indication.


Q: Is Bromhexine the active ingredient in multiple different brand names?

Yes, official drug listings confirm that Bromhexine Hydrochloride is the single active ingredient used in numerous different pharmaceutical products. These products are marketed and sold globally under various distinct brand names.


Q: Do you need a prescription for Bromhexine in the United States?

According to FDA records, Bromhexine is not currently available as a licensed single-ingredient drug in the United States. Where it is licensed internationally, it is widely marketed and sold as an over-the-counter (non-prescription) medicine.


Q: What should be done if someone accidentally takes too much Bromhexine?

Regulatory guidance on overdose generally states that no unique symptoms have been reported in humans beyond known side effects, which may be intensified. Symptomatic medical treatment should be sought immediately if accidental overuse occurs, according to official directives.


Q: Why might a person not feel the effects of Bromhexine right away?

Even though the drug is quickly absorbed into the body, the process of chemically breaking down thick mucus and stimulating secretion takes time. Due to this therapeutic action, it may take two to three days for the full effects to become clearly noticeable.

--ôs--

Q: Is there any difference in how Bromhexine works in children compared to adults?

The fundamental mechanism by which Bromhexine acts to break down mucus is the same across all approved age groups. Regulatory safety data indicates that in clinical experience, children and adults have shown similar patterns of adverse reactions, with age-specific doses used for safety management.


Q: Does research indicate that Bromhexine is widely studied in multiple countries?

Yes, regulatory documents from international agencies like the European Medicines Agency (EMA) confirm that the data supporting Bromhexine's safety and efficacy is based on numerous clinical studies and reviews originating from different countries.


Q: Can Bromhexine affect sleep patterns?

Official product information, based on adverse reaction listings, does not include changes to sleep patterns—such as severe drowsiness (sedation) or difficulty sleeping (insomnia)—among the commonly or uncommonly reported adverse reactions for Bromhexine.


Q: Does Bromhexine make the throat feel dry?

Adverse reaction listings do not specifically name throat dryness as a common or uncommon side effect of Bromhexine. However, official product information for some formulations does note that a dry mouth has been reported.


Q: Is Bromhexine considered a decongestant?

No, Bromhexine is officially classified as a mucolytic or secretolytic agent because it works to thin and clear secretions from the airways. It is not classified as a decongestant, a class of drug that primarily acts to reduce swelling in the nasal passages.


Q: Does Bromhexine have a specific warning about driving or operating machinery?

Official product information generally does not contain a specific warning against driving or operating heavy machinery. This is based on the fact that the medicine is not typically associated with central nervous system effects like severe drowsiness or impaired alertness.


Q: What type of conditions require the use of Bromhexine under a doctor's supervision?

Regulatory safety warnings advise that the use of this medicine requires conditional caution and often a medical professional's supervision in patients with a history of peptic ulceration or with severe impairment of the liver or kidneys. These conditions may affect the body’s ability to clear the drug.

How should Bromhexine be stored and disposed of?

How to Store and Dispose of Bromhexine?

Bromhexine must be stored according to specific regulatory requirements to maintain its stability.


Storage Requirements

The medicine should be stored at controlled room temperature, generally defined as not exceeding 30 C, though some formulations specify storage below 25 C. The product must be protected from light; liquid forms may require the bottle to be kept within its original outer carton for adequate protection.

It is a mandatory regulatory requirement to keep the medicine out of the sight and reach of children.

Disposal Instructions

Any expired or unused Bromhexine medicinal product must be disposed of in accordance with local requirements. Official instructions often require that pharmaceutical waste material be returned to a local pharmacy or designated collection point rather than being disposed of in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromhexine found in:

A-Z Index: